SEMA G

SEMA G – semaglutide analogue, GLP-1 receptor agonist for metabolic studies

SEMA G is a long-acting semaglutide analogue – an agonist of the GLP-1 receptor (glucagon-like peptide-1 receptor). It is a peptide with a modified structure, designed to extend the half-life compared to native GLP-1. In studies in cellular and animal models, SEMA G activates GLP-1R signaling, modulating metabolic pathways in pancreatic beta cells and other tissues expressing this receptor. SEMA G is not a medicinal product – it is intended for research use only. Browse the available variants in the One Peptides offer.

See also the full section research peptides.

What is SEMA G?

SEMA G is a synthetic, long-acting GLP-1 peptide analogue (glucagon-like peptide-1), belonging to the class of GLP-1 receptor agonists (GLP-1RA). Native GLP-1 is an incretin hormone secreted by L cells of the small intestine in response to the presence of nutrients in the intestinal lumen. Its discovery and characterization of the GLP-1 receptor date back to the 1980s and 1990s.

The main limitation of native GLP-1 is its very short half-life (approximately 2-3 minutes), resulting from rapid degradation by the enzyme DPP-4 (dipeptidyl peptidase IV). SEMA G, as an analogue with a modified structure, has modifications that prevent enzymatic degradation, which significantly extends its period of operation in experimental models.

The mechanism of action of SEMA G is to bind to the GLP-1R receptor, a G protein-coupled receptor (class B GPCR). Activation of GLP-1R triggers a signaling cascade involving the cAMP/PKA pathway, which leads to stimulation of insulin secretion in a glucose-dependent manner in pancreatic beta cells. In studies on cell models, modulation of beta cell proliferation and survival was also observed.

SEMA G variants available

The product is supplied with a Certificate of Analysis (CoA) confirming purity and identity. Detailed specifications can be found on the product card.

Which SEMA G variant should you choose?

SEMA G is available from One Peptides in the form of a lyophilized product containing 2 mg of substance per vial. This amount allows for in vitro tests – GLP-1R receptor activation tests on cell lines (e.g. INS-1, MIN6), cAMP level determinations or beta cell survival tests. The 2 mg content allows you to conduct a series of experiments with many test concentrations and repetitions.

Purity parameters are confirmed by independent HPLC and MS analyses.

How is SEMA G different from similar compounds?

SEMA G vs native GLP-1
Native GLP-1 (7-36 amide or 7-37) is an endogenous incretin hormone with a very short half-life (2-3 minutes) due to rapid degradation by the DPP-4 enzyme. SEMA G, as a long-acting analogue, has structural modifications – including fatty acid chain acylation enabling binding to albumin and amino acid substitutions in positions susceptible to cleavage by DPP-4. These modifications extend the period of action of the compound in experimental models by orders of magnitude, while maintaining high affinity for the GLP-1R receptor. In comparative studies, SEMA G shows prolonged activation of cAMP signaling compared to the native peptide.

SEMA G vs HGH fragment 176-191
This comparison concerns two peptides studied in the context of metabolism, but acting through completely different molecular targets. SEMA G activates the GLP-1R receptor, modulating pathways related to insulin secretion and glucose homeostasis in pancreatic beta cells. HGH fragment 176-191 is a C-terminal fragment of human growth hormone, studied in the context of lipolysis and adipose tissue metabolism, acting independently of the GH receptor. Both peptides therefore represent different approaches to studying metabolic pathways. You can find more information about HGH in the category HGH fragment 176-191.

FAQ – Frequently asked questions

1. How does SEMA G differ from native GLP-1?
SEMA G is a long-acting GLP-1 analogue with structural modifications that prevent degradation by the DPP-4 enzyme. Native GLP-1 has a half-life of approximately 2-3 minutes, while modifications in SEMA G significantly increase this time in experimental models.

2. What is the mechanism of action of SEMA G at the cellular level?
SEMA G binds to the GLP-1R receptor (G protein-coupled receptor, class B) and activates the cAMP/PKA signaling cascade. In pancreatic beta cells, this leads to stimulation of insulin secretion in a glucose-dependent manner. Modulation of pathways related to cell survival was also observed.

3. Is SEMA G a medicinal product?
NO. SEMA G offered at One Peptides is a compound intended solely for research purposes (Research Use Only). It is not a medicine, dietary supplement or product for use on humans.

4. In which research models is SEMA G used?
SEMA G is used in studies on cell lines expressing GLP-1R (e.g. INS-1, MIN6, HEK293-GLP1R), in pancreatic beta cell models, and in animal models to study incretin signaling and metabolic homeostasis.

5. How to store SEMA G?
SEMA G in freeze-dried form should be stored at -20°C, away from light and moisture. After reconstitution, the solution should be stored at 2-8°C and used according to the instructions on the product card. Details can be found in the SDS.

Quality and standards at One Peptides

Each batch of SEMA G undergoes purity analysis by HPLC and molecular weight verification by mass spectrometry (MS). Each order is accompanied by a certificate of analysis (CoA) and a safety data sheet (SDS). Quality control procedures include verification of peptide sequence and batch-to-batch consistency of parameters.